Protocol Ledger

NCT05020236 · Phase III · RECRUITING

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Interventional Phase III clinical trial protocol NCT05020236 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-04 Enrollment: 893 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05020236
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)893 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05020236
Protocol FieldVerified Registry Value
NCT IdentifierNCT05020236
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment893 participants (ESTIMATED)
Registered Start Date2021-10-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05020236
Hospital Research SiteLocationSite Profile
UCHealth Greeley HospitalGreeley, COOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI